Breyanzi (lisocabtagene maraleucel) is now approved for adults with relapsed or refractory follicular lymphoma who have received at least two other systemic therapies, according to a May 15 news release from BMS.
In a clinical trial of 101 patients, 94% of study participants achieved a complete response and 97% showed an overall response rate.
The one-time infusion therapy is also approved for relapsed or refractory large B-cell lymphoma, relapsed or refractory chronic lymphocytic leukemia, and small lymphocytic lymphoma.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
